Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
The Cranbury facility represents a strategic advancement of the company's operations in the Unted States
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Merck will showcase results in innovative solutions in HIV treatment and prevention
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Subscribe To Our Newsletter & Stay Updated
